Pacemaker Pacing Site and Atrial Fibrillation in People With Sinus Node Dysfunction
Compares two atrial pacing sites for preventing atrial fibrillation in people receiving pacemakers.
Plain-language title generated from the registry record
Registry title: Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction
Key facts
- Where
- Anqing, Shanghai, Tongling, Wuhan, and Zunyi, ChinaSee the 10 sites
Where in China
- China Medical University affiliated AnQing Municipal HospitalAnqing, ChinaNot yet recruiting
- Fudan University Affiliated Huadong HospitalShanghai, ChinaNot yet recruiting
- Shanghai Jiaotong University affiliated Shanghai Ninth People's HospitalShanghai, ChinaNot yet recruiting
- Shanghai Jiaotong University affiliated Shanghai Sixth People's HospitalShanghai, ChinaNot yet recruiting
- Shanghai University of Traditional Chinese Medicine affiliated Putuo HospitalShanghai, ChinaNot yet recruiting
- Tong Ren Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
- Tongji University School of Medicine affiliated Tongji UniversityShanghai, ChinaNot yet recruiting
- Tongling People's HospitalTongling, ChinaNot yet recruiting
- Wuhan Asia General HospitalWuhan, ChinaNot yet recruiting
- Affiliated Hospital of Zunyi Medical CollegeZunyi, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Tong Ren Hospital
- Trial code
- NCT07645066
- Record updated
- 23 September 2026
- Original description
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.Read full original descriptionShow less
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
Inclusion: Age ≥18 years; Indication for permanent pacemaker implantation, including:; Sinus node dysfunction, defined as at least one of the following:; Symptomatic sinus bradycardia; Tachy-brady syndrome; Chronotropic incompetence; Sinus pause / arrest; Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned; Expected survival >1 year; Panned implantation of a device capable of detecting atrial high-rate episodes; Willing and able to provide informed consent.
Exclusion: Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation; Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision; Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases; Acute myocardial infarction within 3 months before enrollment; Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D); Any condition that, in the opinion of the investigator, makes participation unsuitable; Persistent left superior vena cava or dextrocardia; Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception; Participation in another clinical trial that may interfere.